Pfizer

Pic:getty/sohelparvezhaque

FDA decision on Pfizer’s maternal RSV vaccine expected by August

By Rachel Arthur

The US Food and Drug Administration (FDA) has accepted Pfizer’s Biologics License Application (BLA) for its maternal RSV vaccine under priority review. If approved, the vaccine will become the first RSV vaccine for pregnant women to protect against RSV...

Pic:getty/andrewbrookes

FDA expected to make decision on GSK’s RSV vaccine in May

By Rachel Arthur

The US Food and Drug Administration (FDA) has granted Priority Review to GSK’s respiratory syncytial virus (RSV) older adult vaccine candidate with a decision expected in May 2023: which could make it the first vaccine approved against the virus.

© GettyImages/skodonnell

Pfizer to raise COVID-19 vaccine price in US

By Jane Byrne

As the US government stops buying COVID-19 shots, Pfizer said the vaccine it developed with BioNTech will be sold for US$110 to US$130 per dose, from as early as the first quarter 2023.

Pic:getty/tosho

Pfizer and BioNTech submit Omicron booster EUA application to US FDA

By Rachel Arthur

Pfizer and BioNTech have completed their application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine: saying they stand ready to start shipping...

Pic:getty/hailshadow

Pfizer invests $95m in Valneva

By Rachel Arthur

Pfizer will invest €90.5m ($95m) in French vaccine specialist Valneva, representing 8.1% of Valneva’s share capital. The investment will support the duo’s Lyme disease vaccine partnership.

Pic:getty/sohelparvezhaque

Pfizer acquires RSV therapeutic candidates

By Rachel Arthur

Pfizer will acquire ReViral, a privately-held clinical-stage company which is focused on novel antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525m.

Pic:getty/remotevtx

Pfizer sets out strategy to win in mRNA

By Rachel Arthur

Having built up its mRNA expertise with its COVID-19 vaccine, Pfizer now sets out its strategy for the future. “Going forward, we plan to continue to capitalize on the leadership we have built in both mRNA R&D and manufacturing."